Equites Radar

LMAT · LeMaitre Vascular, Inc.

Medical Instruments & SuppliesUnited StatesAnalyst view: Buy

$80.59

+2.27% last session

End-of-day data · close of 2026-09-11

Bearish1 bullish · 4 bearish technical signals
Consensus: Buy (2.25 from 7 analysts)
To mean target: +35.8%

Market cap

$2B

Enterprise value

$2B

Trailing P/E

27.8

Forward P/E

24.8

Dividend yield

1.0%

Beta

0.49

Avg volume

0M

Employees

1K

Daily Change %

2.27%

5 Days Change

-1.49%

10 Days Change

-1.01%

30 Days Change

-3.78%

60 Days Change

-22.42%

Month to Day Change

-1.99%

Year to Day Change

-1.25%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.25
Covering analysts7
Mean price target$107.00
Low price target$81.00
Upside to mean target+35.8%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)41.9
50-day MA$90.19
200-day MA$94.35
Price vs 50-day MA-10.6%
Price vs 200-day MA-14.6%
MACD histogram0.54
Volume vs 3-month avg0.8×
52w low $78.7652w high $116.75

Analyst sentiment over time — LMAT

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-08-05

Latest call per bank · past 12 months

Wells Fargo

Equal-Weight

$94.00

+19.3% vs price
▼ cut from $104Maintains · 2026-08-05

Recent rating actions

DateFirmActionRatingPrice target
2026-08-05Wells FargoMaintainsEqual-Weight$104 $94.00
2026-06-03Barrington ResearchMaintainsOutperform$120
2026-05-06Barrington ResearchMaintainsOutperform$105 $120
2026-05-06CitizensMaintainsMarket Outperform$118 $127
2026-05-06Wells FargoMaintainsEqual-Weight$94.00 $104
2026-02-26Barrington ResearchMaintainsOutperform$95.00 $105
2026-02-26Roth CapitalReiteratesBuy$108 $117
2026-02-26Wells FargoMaintainsEqual-Weight$87.00 $94.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-09-11

  • RSI (14): RSI is 42 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 10.6% below the 50-day MA ($90.19).
  • Price vs 200-day MA: Trading 14.6% below the 200-day MA ($94.35).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+0.54) — short-term momentum is improving.
  • 52-week range: Price is within 10% of the 52-week low ($78.76).

LMAT Price Chart

Loading chart for LMAT

Fundamentals

Revenue (TTM)$0M
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$18.38
Net Debt / EBITDA-2.2
WACC8.0%
Revenue growth10.00%
Earnings growth23.00%

About LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

More in Medical Instruments & Supplies

Screen LMAT against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.